Key points are not available for this paper at this time.
, which not only enhanced the stability and cellular uptake of the agonists but also amplified the antitumor immunity by concurrently activating the stimulator of interferon genes (STING) and toll-like receptor 9 (TLR9) pathways. Intratumoral injection of Mn-MNAs significantly inhibited tumor growth and fostered an immune-supportive tumor microenvironment in the CT26 tumor model. Intravenous administration of Mn-MNAs achieved remarkable therapeutic efficacy in the B16F10 melanoma model, which was further enhanced upon combination with a checkpoint blockade. Overall, multivalent nanoagonists open new avenues for cancer metalloimmunotherapy.
Huang et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: